SAN DIEGO, Sept. 17 /PRNewswire/ -- CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care, tissue repair, and inflammation, today announced that its wound healing gel, NEXAGON®, has been named one of Windhover Therapeutic Area Partnership's "Top HOT SPACE Projects to Watch." This list handpicked by Windhover and independent consultants, represents the top 10 product candidates that are available for partnering in ophthalmology, orphan diseases, women's health, and other categories.
Past Windhover Top 10 candidates have signed a total potential value of $17 billion in acquisitions and alliances.
NEXAGON was chosen for inclusion by Windhover and Catharine Staughton, a founder of Scisive Consulting, LP, a professional and management consulting company dedicated to serving the medical and life sciences industries. The selection followed review of CoDa Therapeutics' technology and positive results from its Phase 2 Study of NEXAGON in patients with chronic venous leg ulcers. In this randomized, vehicle-controlled, double-blind study, NEXAGON was shown to be safe and tolerable, and showed a statistically significant 5-fold improvement over vehicle in the endpoint of complete healing, with just three doses of drug administered over 4 weeks. NEXAGON also demonstrated a clinically meaningful improvement in wound surface area reduction that was statistically significant for ulcer sizes representing the bulk of the market with a 71% reduction in wound size at 4 weeks.
Bradford Duft, President and CEO of CoDa said, "We are very pleased to be named to Windhover's prestigious list of top 10 HOT SPACE product candidates. In prior years, this list included many of today's biopharmaceutical industry leaders and partnered products. With our upcoming participation in Windhover's Therapeutic Area Partnership conference, the timing of this distinction is ideal as we continu
|SOURCE CoDa Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved